As HRD1 and SEL1L are critical molecules for neurodegenerative disorders such as PD, luteolin might be a therapeutic drug candidate for the treatment of PD and other neurodegenerative disorders whose neuropathology implicates the ER stress. This evidence concerns the gene SEL1L and Parkinson disease.